Gene: MAP3K20

51776
AZK|CNM6|MLK7|MLT|MLTK|MLTKalpha|MLTKbeta|MRK|SFMMP|ZAK|mlklak|pk
mitogen-activated protein kinase kinase kinase 20
protein-coding
2q31.1
Ensembl:ENSG00000091436 MIM:609479 Vega:OTTHUMG00000132297 UniprotKB:Q9NYL2
NG_029373.1
SNP Mapped
1   ANCO-SNPs
AD
0   
NA (AD)  NA (ND)   (Frontal_Cortex)
3.932e-1 (AD)  6.341e-1 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs6761224chr2:173261232 (GRCh38.p7)T>Calcohol dependenceSNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Drugs/Compounds

ID Drug Name Drug Type CAS Num Status Role
DB01254DasatinibSmall Molecule302962-49-8Approved|InvestigationalTarget
ID Drug Name Action PubMed
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP3K20 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP3K20 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP3K20 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP3K20 mRNA"27188386
C0275764-hydroxy-2-nonenal4-hydroxy-2-nonenal results in decreased expression of MAP3K20 mRNA19191707
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP3K20 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP3K20 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP3K20 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP3K20 mRNA"27188386
D000082AcetaminophenAcetaminophen results in decreased expression of MAP3K20 mRNA21420995
D016604Aflatoxin B1Aflatoxin B1 results in decreased methylation of MAP3K20 gene27153756
D000841AnisomycinMAP3K20 protein promotes the reaction [Anisomycin results in increased phosphorylation of and results in increased activity of MAPK8 protein]15737997
D000841Anisomycinquinoline analog inhibits the reaction [MAP3K20 protein promotes the reaction [Anisomycin results in increased phosphorylation of and results in increased activity of MAPK8 protein]]15737997
D018501Antirheumatic AgentsAntirheumatic Agents results in increased expression of MAP3K20 mRNA24449571
D017638Asbestos, Crocidolite"Asbestos, Crocidolite affects the expression of MAP3K20 mRNA"17331233
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of MAP3K20 mRNA20106945|2163298
D0151237,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide"7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in decreased expression of MAP3K20 mRNA"20018196
D004958EstradiolEstradiol results in increased expression of MAP3K20 mRNA23373633
C044887beta-methylcholinebeta-methylcholine affects the expression of MAP3K20 mRNA21179406
C018475butyraldehydebutyraldehyde results in decreased expression of MAP3K20 mRNA26079696
D002392Catechin[Catechin co-treated with Grape Seed Proanthocyanidins] results in increased expression of MAP3K20 mRNA24763279
C074702chromium hexavalent ionchromium hexavalent ion results in increased expression of MAP3K20 mRNA27793765
D003300Copper[Disulfiram binds to Copper] which results in increased expression of MAP3K20 mRNA24690739
D016572CyclosporineCyclosporine results in increased expression of MAP3K20 mRNA20106945|2556210
D000069439DasatinibDasatinib binds to MAP3K20 protein18180381
D002117CalcitriolCalcitriol results in decreased expression of MAP3K20 mRNA21592394
D002117Calcitriol[Testosterone co-treated with Calcitriol] results in decreased expression of MAP3K20 mRNA21592394
D004221Disulfiram[Disulfiram binds to Copper] which results in increased expression of MAP3K20 mRNA24690739
C118739entinostatentinostat results in decreased expression of MAP3K20 mRNA26272509
C118739entinostat"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP3K20 mRNA"27188386
C082360fipronilfipronil results in increased methylation of MAP3K20 gene28536466
D016650Fluorescein-5-isothiocyanateFluorescein-5-isothiocyanate binds to MAP3K20 protein27129696
D005472FluorouracilFluorouracil affects the expression of MAP3K20 mRNA16584549
C511402Grape Seed Proanthocyanidins[Catechin co-treated with Grape Seed Proanthocyanidins] results in increased expression of MAP3K20 mRNA24763279
C492448ICG 001ICG 001 results in increased expression of MAP3K20 mRNA26191083
D007854LeadLead results in decreased expression of MAP3K20 mRNA19921347
C406082monomethylarsonous acidmonomethylarsonous acid results in decreased expression of MAP3K20 mRNA20886546
C005246myristicinmyristicin results in decreased expression of MAP3K20 mRNA24792648
D037742Nanotubes, Carbon"Nanotubes, Carbon analog results in decreased expression of MAP3K20 mRNA"21624382
D009532NickelNickel results in decreased expression of MAP3K20 mRNA25583101
C030110oxaliplatinoxaliplatin results in decreased expression of MAP3K20 mRNA16510598
D052638Particulate MatterParticulate Matter results in decreased expression of MAP3K20 mRNA17987463
D010662Phenylmercuric Acetate"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP3K20 mRNA"27188386
D010662Phenylmercuric AcetatePhenylmercuric Acetate results in increased expression of MAP3K20 mRNA26272509
C006253pirinixic acid[pirinixic acid binds to and results in increased activity of PPARA protein] which results in decreased expression of MAP3K20 mRNA19710929
C037219quinolinequinoline analog inhibits the reaction [MAP3K20 protein promotes the reaction [Anisomycin results in increased phosphorylation of and results in increased activity of MAPK8 protein]]15737997
C037219quinolinequinoline analog results in decreased activity of MAP3K20 protein15737997
D020849Raloxifene HydrochlorideRaloxifene Hydrochloride results in decreased expression of MAP3K20 mRNA19429434
C547185riccardin Driccardin D results in increased expression of MAP3K20 mRNA24069304
D012822Silicon DioxideSilicon Dioxide analog results in decreased expression of MAP3K20 mRNA25895662
D013629TamoxifenTamoxifen results in decreased expression of MAP3K20 mRNA19429434
D013739Testosterone[Testosterone co-treated with Calcitriol] results in decreased expression of MAP3K20 mRNA21592394
D013739TestosteroneTestosterone results in decreased expression of MAP3K20 mRNA21592394
C012589trichostatin A"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP3K20 mRNA"27188386
C012589trichostatin Atrichostatin A affects the expression of MAP3K20 mRNA28542535
C012589trichostatin Atrichostatin A results in increased expression of MAP3K20 mRNA26272509
C057693troglitazonetroglitazone results in decreased expression of MAP3K20 mRNA28973697
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP3K20 mRNA"27188386
D014635Valproic AcidValproic Acid affects the expression of MAP3K20 mRNA25979313
D014635Valproic AcidValproic Acid results in increased expression of MAP3K20 mRNA24383497|2627250
D001335Vehicle EmissionsVehicle Emissions results in decreased expression of MAP3K20 mRNA17987463
D001335Vehicle EmissionsVehicle Emissions affects the methylation of MAP3K20 gene25560391

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0000287magnesium ion binding-IDA11836244  
GO:0003723RNA binding-HDA22681889  
GO:0004674protein serine/threonine kinase activity-IDA11836244  
GO:0004709MAP kinase kinase kinase activity-IDA11836244  
GO:0005515protein binding-IPI21988832  
GO:0005524ATP binding-IDA11836244  
GO ID GO Term Qualifier Evidence PubMed
GO:0000077DNA damage checkpoint-IMP11836244  
GO:0000186activation of MAPKK activity-TAS11836244  
GO:0006468protein phosphorylation-IDA11836244  
GO:0007010cytoskeleton organization-IEA-  
GO:0007050cell cycle arrest-IMP11836244  
GO:0007093mitotic cell cycle checkpoint-IDA15342622  
GO:0007257activation of JUN kinase activity-IDA11836244  
GO:0008219cell death-NAS11836244  
GO:0008283cell proliferation-NAS11836244  
GO:0030154cell differentiation-NAS11836244  
GO:0042733embryonic digit morphogenesis-IMP26755636  
GO:0043065positive regulation of apoptotic process-IDA10924358  
GO:0051403stress-activated MAPK cascade-IDA11836244  
GO:0060173limb development-IMP26755636  
GO:0071480cellular response to gamma radiation-IDA11836244  
GO ID GO Term Qualifier Evidence PubMed
GO:0005634nucleus-IEA-  
GO:0005737cytoplasm-ISS-  
GO:0005829cytosol-IDA-  
KEGG ID KEGG Term
hsa04010MAPK signaling pathway
hsa04530Tight junction
Reactome ID Reactome Term Evidence

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal